Eli Lilly sued four telehealth firms, but it is adopting a new legal strategy in its fight against compounded GLP-1s.

Private equity activity in healthcare remained resilient with 42 deals worth $562 million, just shy of last quarter’s $603 ...

Dr. Rietiker has considerable experience in the life sciences industry, including leadership positions in global pharmaceutical and medical device companies, and has overseen multiple major company ...

Eli Lilly ( LLY 1.21%) and Novo Nordisk ( NVO 2.66%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

Talks continue between the U.S. and China on tackling the fentanyl epidemic amid the bitter trade war between the world’s two ...

Our writer celebrates being average and looks at one FTSE 100 stock that could help investors navigate their way through the minefield of Trump’s tariffs.

To mitigate the impact of potential tariffs, market diversification strategies are essential. Indian pharmaceutical firms can ...

European pharmaceutical bosses have called on the EU to increase drug prices towards the much higher levels paid by the US, ...

The pharma giant said the investment would create more than 12,000 jobs, as it joins rival Novartis in expanding its ...

Health officials in US President Donald Trump's administration are reportedly exploring an international reference pricing ...

Two years ago, the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group faced a mini-exodus as several ...

Pharmaceutical Technology® Group spoke with Erik Wiklund, CEO of Circio, about the future of M&A in the bio/pharmaceutical industry and the struggle small biotech companies face raising funds.